Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at approximately $63 million by the Biomedical Advanced Research and Development Authority (BARDA) to develop an antidote spray device for the treatment of known or suspected acute cyanide poisoning. The single-use intranasal spray device will deliver a stabilized form of isoamyl nitrite (SIAN) and is intended for use by first responders and medical personnel following a cyanide incident.
{iframe}http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=RssLanding&cat=news&id=2301191{/iframe}